R&D News | pharmaphorum

News

Africa-led HIV vaccine trial ends in failure

A trial viewed as the best hope of finding an effective HIV vaccine this decade has ended in failure in another major setback for the field.

News

Regeneron bids to join the BCMA bispecific camp

Regeneron has moved closer to a regulatory filing for its BCMAxCD3 bispecific antibody linvoseltamab, the first of a series of bispecifics that is spearheading its oncolog

News

Trial finds Lilly’s Olumiant could treat type 1 diabetes

Treatment with Eli Lilly’s JAK inhibitor Olumiant has been shown to preserve the function of insulin-producing pancreatic beta cells in patients with type 1 diabetes, pote

News

Sanofi says new drugs can add €10bn to sales by 2030

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of th

News

AbbVie swoops on Pfizer spin-out Cerevel with $8.7bn offer

AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, w

News

Merck pummelled as MS hope evobrutinib dies in phase 3

Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib missed the mark in two phase 3 trials, spelling th

Africa-led HIV vaccine trial ends in failure

Regeneron bids to join the BCMA bispecific camp

Trial finds Lilly’s Olumiant could treat type 1 diabetes

Sanofi says new drugs can add €10bn to sales by 2030

AbbVie swoops on Pfizer spin-out Cerevel with $8.7bn offer

Merck pummelled as MS hope evobrutinib dies in phase 3

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks